P rimary percutaneous coronary intervention (PCI), when available, is the most effective method of achieving reperfusion in patients with ST-segment elevation myocardial infarction (STEMI). 1 However, a major limitation of primary PCI is the possibility of distal embolization of thrombus and failure to restore flow at the microvascular level. Measures of microvascular tissue reperfusion, such as the degree of ST-segment resolution or angiographic myocardial blush grade, have been shown to predict the rate of death after primary PCI. 2, 3 Removal of the thrombus by manual thrombectomy before stent deployment has the potential of reducing distal embolization and improving microvascular perfusion. Small, randomized trials of thrombectomy have shown improvements in markers of tissue reperfusion. 4 The Thrombus Aspiration during Percutaneous Coronary Intervention in Acute Myocardial Infarction Study (TAPAS) showed improved myocardial blush grade (the primary outcome) and lower mortality with thrombectomy. 5, 6 Practice guidelines were subsequently changed to recommend routine manual thrombectomy. 7, 8 As a result, thrombectomy has become a part of clinical practice and its use has grown rapidly.
After the publication of the TAPAS findings, meta-analyses suggested that thrombectomy might increase the risk of stroke, but this finding was cautiously interpreted because it was based on small numbers of events. 9 Subsequently, the recent large Thrombus Aspiration in ST-Elevation Myocardial Infarction in Scandinavia (TASTE) trial showed no reduction in mortality at 30 days or 1 year with routine thrombectomy. 10, 11 Although an updated meta-analysis of thrombectomy that included the TASTE trial continued to suggest that a modest but clinically important benefit is possible, 12 the efficacy of this procedure remains uncertain.
Me thods

Study Design
The Trial of Routine Aspiration Thrombectomy with PCI versus PCI Alone in Patients with STEMI (TOTAL) was an international, investigator-initiated, multicenter, prospective, randomized trial of upfront manual aspiration thrombectomy with the Export catheter (Medtronic) versus PCI alone. This was an open trial with blinded adjudication of outcomes. The trial design was published previously. 13 The study was approved by the ethics committee at each participating center and by national regulatory authorities where required. The academic steering committee designed the trial protocol, which is available with the full text of this article at NEJM.org. An independent data and safety monitoring committee oversaw the safety of the trial. The Population Health Research Institute, a joint institute of McMaster University and Hamilton Health Sciences, conducted and coordinated the trial and also collected and held all trial data. The trial statisticians conducted all analyses (for details, see the Supplementary Appendix, available at NEJM.org). The trial's principal investigators vouch for the integrity and completeness of the data and analyses, as well as for the fidelity of this report to the trial protocol, and made the decision to submit the manuscript for publication. One of the principal investigators prepared the first draft of the manuscript, which was then reviewed and edited by the coauthors.
Funding was provided by Medtronic and the Canadian Institutes of Health Research (CIHR) and the Canadian Network and Centre for Trials Internationally, an initiative funded by the CIHR. Medtronic agreed to provide funding on the basis of a review of the protocol developed by the steering committee and to increase funding on the basis of the steering committee's justifications for an increased sample size; company representatives also reviewed the analyses conducted by the trial statisticians and had the right to review but not to provide or deny approval of the final manuscript.
Patients and Randomization
Patients with STEMI who were referred for primary PCI within 12 hours after the onset of symptoms were eligible to participate in the trial. Patients who had undergone previous coronaryartery bypass grafting or those who had received fibrinolytic therapy were not eligible. (See Table  S1 in the Supplementary Appendix for detailed inclusion and exclusion criteria.) All patients provided written informed consent.
Eligible patients were randomly assigned in a 1:1 ratio to undergo either thrombus aspiration followed by PCI or PCI alone. Randomization was performed with the use of permuted blocks with stratification according to study center with the use of a 24-hour computerized central system located at the Population Health Research Institute. All patients and investigators were aware of study-group assignments.
Thrombectomy Procedure
The study protocol and investigator guidance documents specified standard procedures for thrombectomy. After the lesion was crossed with a guidewire, the thrombectomy device was to be advanced and suction started before it crossed the lesion. If the operator was unable to cross the lesion with the thrombectomy catheter, predilation with a small-diameter balloon was to be performed, followed by another attempt at thrombectomy. It was recommended that the guide catheter be fully engaged with the coronary ostium during removal of the thrombectomy catheter in order to avoid embolizing thrombus to the systemic vasculature. After thrombectomy, the guide catheter was to be aspirated to ensure removal of air or thrombus. Locally approved Export aspiration catheters (6 or 7 French), including the XT, AP, and ADVANCE, were to be used for the thrombectomy procedure. The PCI procedure was performed after thrombus aspiration was completed.
PCI Alone
The PCI-alone group underwent the procedure according to the operator's usual technique without thrombectomy. Bailout thrombectomy was allowed if there was failure of the initial PCI-alone strategy, defined as either Thrombolysis in Myocardial Infarction (TIMI) flow of 0 or 1 (on a scale of 0 to 3, with a higher grade indicating better flow) with a large thrombus after balloon predilation or the persistence of a large thrombus after stent deployment.
Study Outcomes
The primary efficacy outcome was death from cardiovascular causes, recurrent myocardial infarction, cardiogenic shock, or new or worsening New York Heart Association (NYHA) class IV heart failure within 180 days. Key secondary outcomes were the primary efficacy outcome plus stent thrombosis or target-vessel revascularization within 180 days and cardiovascular death within 180 days. The key safety outcome was stroke within 30 days, and the key net-benefit outcome was the occurrence of the primary outcome or stroke within 180 days.
A central committee whose members were unaware of study-group assignments adjudicated all the primary-outcome events, strokes, transient ischemic attacks, major bleeding, target-vessel revascularization, and stent thromboses. Detailed outcome definitions have been reported previously 13 ( Table S2 in the Supplementary Appendix).
ST-segment resolution and angiographic outcomes were reported by investigators. Core laboratory analyses of electrocardiographic and angiographic data are ongoing and not yet available. The angiographic core laboratory assessed thrombus grade in a subgroup of patients for quality assurance; details of this process are available in the Supplementary Appendix.
Subgroup Analyses
Since we had hypothesized that thrombectomy would be more beneficial among patients with a high thrombus burden, the main subgroup analysis was based on the TIMI thrombus grade (grade <3 vs. grade ≥3), which was determined after the first injection of contrast material in the infarctrelated artery before wire crossing. Other prespecified subgroups included TIMI thrombus grade (grade <4 vs. grade ≥4), symptom onset (<6 hours vs. 6 to 12 hours), initial TIMI flow (0 to 1 vs. 2 to 3), age (≤65 years vs. >65 years), centers divided into three groups of volume of primary PCI procedures, and type of myocardial infarction (anterior vs. nonanterior).
Statistical Analysis
According to the original sample-size calculations, which were based on a rate of the primary outcome of 14% at 180 days, we estimated that 4000 patients would be required for the study to have a power of 80% to detect a relative reduction of 25% in risk. On the basis of a blinded interim analysis showing an overall event rate of 7%, we estimated that 10,700 patients would be needed for 718 primary outcome events to occur, which would provide a power of 80% to detect a relative reduction of 20% in risk. The sample size was increased without knowledge of any treatment effects.
For the primary analysis, a modified inten- tion-to-treat analysis was prespecified to include only patients who had undergone randomization and primary PCI. Data were to be analyzed in the treatment group to which patients were originally assigned. Patients who had not undergone PCI for the index STEMI (e.g., those with normal coronary arteries) were not included in the primary analysis. Other prespecified sensitivity analyses included full intention-to-treat, as-treated, and per-protocol analyses. In the astreated analysis, all patients who underwent thrombectomy (either upfront or bailout), regardless of their study-group assignment, were compared with patients who had undergone PCI without thrombectomy. The per-protocol analysis included all patients who had undergone PCI and did not cross over from their initial studygroup assignment to the alternative therapy. We used a two-sided, log-rank test to compare the two groups; a P value of less than 0.05 was considered to indicate statistical significance. We used a Cox proportional-hazards regression model with the treatment group as the predictor variable to estimate hazard ratios and 95% confidence intervals.
R esults
Patient and Procedure Characteristics
From August 2010 through July 2014, a total of 10,732 patients were enrolled at 87 hospitals in 20 countries; 5372 patients were assigned to undergo thrombectomy followed by PCI, and 5360 were assigned to undergo PCI alone ( Fig. S1 in the Supplementary Appendix). Of these patients, 10,063 (93.8%) underwent PCI for the index STEMI (5033 in the thrombectomy group and 5030 in the PCI-alone group) and were included in the primary analysis. The rate of crossover was 4.6% (230 patients) from thrombectomy to PCI alone and 1.4% (69 patients) from PCI alone to thrombectomy. Bailout thrombectomy was performed in 355 patients (7.1%) in the PCI-alone group.
Baseline characteristics were well balanced between the two groups except for the proportion of smokers, which was lower in the thrombectomy group (44.6% vs. 46.8%, P = 0.03) ( Table 1 ) and the interval from symptom onset to hospital arrival, which was longer in the thrombectomy group (128 vs. 120 minutes, P = 0.02) ( Table 2 ). The majority of patients (78.4%) had a high thrombus burden, as defined by TIMI thrombus grade 4 or 5, with similar proportions in the two groups.
The rate of use of glycoprotein IIb/IIIa inhibitors was lower in the thrombectomy group than in the PCI-alone group (37.4 vs. 41.4%, P<0.001). Direct stenting was performed more frequently in the thrombectomy group (38.3% vs. 21.3%, P<0.001). The PCI procedure time was longer in the thrombectomy group (39 minutes vs. 35 minutes, P<0.001). In the thrombectomy group, success in crossing the target lesion with the Export catheter at first attempt was observed in 82.5% of patients and in an additional 5.9% after balloon predilation. The use of evidence-based therapies at discharge was similar in the two groups ( Table S3 in the Supplementary Appendix).
Electrocardiographic and Angiographic Outcomes
The rate of incomplete ST-segment resolution (less than 70%) was 27.0% in the thrombectomy group versus 30.2% in PCI-alone group (P<0.001). Rates of TIMI 3 flow after PCI were the same (93.1%) in the two groups (P = 0.12), and were similar for no-reflow rates on angiography (2.4% vs. 2.8%, P = 0.28). The rate of distal embolization was reduced with thrombectomy (1.6% vs. 3.0%, P<0.001). There were no significant betweengroup differences in target-vessel dissection, left main coronary-artery dissection, or thrombus embolization to the left main coronary artery.
Efficacy and Safety
The rate of the primary outcome of cardiovascular death, recurrent myocardial infarction, cardiogenic shock, or NYHA class IV heart failure within 180 days in patients who underwent PCI for index STEMI was 6.9% in the thrombectomy group versus 7.0% in the PCI-alone group (hazard ratio in the thrombectomy group, 0.99; 95% confidence interval [CI], 0.85 to 1.15; P = 0.86) ( Table 3 and Fig. 1A) . The secondary outcome of a combination of the primary outcome and stent thrombosis or target-vessel revascularization within 180 days occurred in 9.9% of patients in the thrombectomy group and 9.8% of patients in PCI-alone group (hazard ratio, 1.00; 95% CI, 0.89 to 1.14; P = 0.95).
Cardiovascular mortality was similar in the two groups within 30 days (2.3% with thrombectomy vs. 2.8% with PCI alone; hazard ratio, 0.83; 95% CI, 0.65 to 1.06; P = 0.13) and within 180 days (3.1% vs. 3.5%; hazard ratio, 0.90; 95% CI, 0.73 to 1.12; P = 0.34), as were the other components of the primary and secondary outcomes and major bleeding ( Table 3, and Table S4 in the Supplementary Appendix).
Within 30 days, stroke occurred in 0.7% of patients in the thrombectomy group and 0.3% of the patients in the PCI-alone group (hazard ratio, 2.06; 95% CI, 1.13 to 3.75; P = 0.02). Within 180 days, stroke occurred in 52 patients (1.0%) in the thrombectomy group and 25 patients (0.5%) in the PCIalone group (hazard ratio, 2.08; 95% CI, 1.29 to 3.35; P = 0.002) (Fig. 1B) . The rate of the net-benefit outcome (the primary outcome plus stroke within 180 days) was similar in the two groups ( Table 3) .
The results of the intention-to-treat, as-treated, and per-protocol analyses were consistent with those of the primary analysis ( Table S5 in the Supplementary Appendix). The primary outcome within 180 days was consistent across all prespecified subgroups, including patients who had high thrombus burden (Fig. 2) .
Discussion
In our trial, a strategy of routine manual thrombectomy during primary PCI did not reduce the risk of the primary outcome of cardiovascular death, recurrent myocardial infarction, cardiogenic shock, or NYHA class IV heart failure within 180 days, as compared with a strategy of PCI alone with thrombectomy permitted only as bailout. This finding was consistent in patients with a high thrombus burden, the group that might be expected to have the most benefit from thrombus aspiration. Stroke rates were higher in pa-tients who had undergone routine thrombectomy than in those who underwent PCI alone. The findings of our trial with regard to the efficacy of thrombectomy are consistent with those of the TASTE trial and the Intracoronary Abciximab and Aspiration Thrombectomy in Patients with Large Anterior Myocardial Infarction (INFUSE-AMI) trial. 10, 14 Our study was the largest of these three trials and thus had the most power to detect a benefit, since it was designed to detect a relative reduction of 20% in the risk of the composite primary outcome. In addition, our trial, unlike the TASTE trial, used detailed event definitions, and the outcomes were adjudicated in a blinded fashion by an independent central committee rather than relying on registry data.
The improvements in ST-segment resolution and distal embolization that were observed with manual thrombectomy in our trial did not translate into clinical benefits. This finding cautions against changing practice on the basis of trials showing an improvement in surrogate outcomes. In addition, although our results for ST-segment resolution are consistent with those of the substantially smaller TAPAS trial, 5 we did not confirm their finding of a reduction in cardiac mortality, 6 a result that emphasizes the importance of conducting large, multicenter trials to verify findings of smaller trials. In TOTAL, stroke was a prespecified safety outcome because previous meta-analyses had suggested an increased risk of stroke with thrombectomy, 9 and we indeed found a higher rate of stroke among patients in the thrombectomy group. It may be hypothesized that if the primary mechanism of stroke were embolization of thrombus or air to the brain during the procedure, then the excess strokes would have occurred predominantly within 24 hours after the procedure or at least during the initial hospitalization. Therefore, our finding of a continued increase in the rate of stroke between 30 and 180 days cannot be easily explained. We cannot completely rule out the play of chance as the explanation for our findings with respect to stroke, given the relatively small number of events.
The TASTE trial showed no difference in stroke rates (0.5% vs. 0.5%), but strokes were reported only during the initial hospitalization. 10 Further data from the TASTE trial regarding stroke rates at 30 and 180 days will be important. In our study, the rates of stroke in both groups (1.0% in the thrombectomy group and 0.5% in the PCI-alone group at 180 days) are consistent with those observed in previous studies (ranging from 1.3 to 2.0%). 15, 16 Several limitations of our study should be taken into account. First of all, the treating interventional cardiologists were aware of studygroup assignments, which could have led to bi-ases in management. For example, the lack of blinding may account for the lower rate of use of glycoprotein IIb/IIIa inhibitors in the thrombectomy group; however, this difference is quite modest and unlikely to have had an effect on the outcomes of the trial.
Second, the inclusion of some patients with a low thrombus burden may have resulted in a patient population that would be less responsive to thrombectomy. However, we observed similar outcomes regardless of the initial thrombus burden. We did not reclassify the TIMI thrombus grade after wire crossing or small-diameter balloon inflation. We therefore cannot exclude a benefit of thrombectomy in patients with a persistent thrombus burden after wire crossing. However, in the TASTE trial, investigators graded the thrombus burden after wire crossing and did not observe a benefit for manual thrombectomy in such patients. 10 Third, our trial evaluated a strategy of routine upfront thrombectomy versus PCI alone with thrombectomy reserved as bailout; it did not study the effect of selective use of thrombectomy versus no thrombectomy. Finally, there was no systematic collection of screening logs, so we cannot provide the number or characteristics of patients who were screened for inclusion as compared with those who underwent randomization.
In conclusion, in patients with STEMI who were undergoing PCI, a strategy of routine manual thrombectomy did not reduce the risk of cardiovascular death, recurrent myocardial infarction, cardiogenic shock, or class IV heart failure within 180 days, as compared with a strategy of PCI alone with only bailout thrombectomy. Routine thrombectomy was associated with an increased rate of stroke within 30 days.
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